THE HAGUE, The Netherlands, Sept. 30, 2021 /PRNewswire/ — Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.
Endolysins as precision anti-bacterials
In its search for solutions, Micreos’ researchers, in close collaboration with the Swiss Federal Technology Institute ETH Zurich, turned to nature’s own precision anti-bacterials, named endolysins. Unlike antibiotics, these highly specific enzymes have the ability to target only unwanted bacteria, while preserving the microbiome, comprising billions of ‘good’ bacteria, essential for our health. Endolysins are safe and environmentally friendly. Because of their working mechanism, development of resistance is not expected.
Addressing unmet medical needs
XZ.700 targets Staphylococcus aureus (S. aureus), including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be beneficial on the skin and conducive to wound healing. SP.800 targets all staphylococcal species … read more